Recent Updates
Recently added Catalysts

AVZO-103

Phase 1

Solid Tumor Cancer | Small molecule | Oncology |cbdMD, Inc.|Last Updated: Aug 25, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLEDBiomarker
Total Trials1
Total Enrollment355

FDA Designations

No designations recorded

Clinical trial landscape

AVZO-103 · 1 trial · 4 indications

Phase 1 1
NCT07193511BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)Solid Tumor Cancer
RECRUITING355 Analytics
PHASE1RECRUITING
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Solid Tumor Cancer
NCT07193511355
Unlock trial analytics

Study Endpoints

Primary Endpoints

Occurrence of Dose Limiting Toxicities (DLTs) during the first cycle (Phase 1)
Approximately 2 years

Number of participants with DLTs assessed for severity using CTCAE v5.0 criteria will be summarized by dose level.

Determine the maximum tolerated dose (MTD) and/or preliminary recommended Phase 2 dose (RP2D) (Phase 1)
Approximately 16 months
Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 1)
From baseline until end of study treatment or study completion (approximately 2 years)
Objective Response Rate (ORR) (Phase 2)
From baseline through disease progression or study completion (approximately 2 years)

Defined as the proportion of patients with a confirmed Complete Response (CR) or Partial Response (PR), as determined by the investigator by radiographic disease assessment according to RECIST v1.1.

Secondary Endpoints

Objective Response Rate (ORR) (Phase 1)
From baseline through disease progression or study completion (approximately 2 years)
Duration of Response (DOR) (Phase 1 and 2)
From baseline through disease progression or study completion (approximately 2 years)
Disease Control Rate (DCR) (Phase 1 and 2)
From baseline through disease progression or study completion (approximately 2 years)
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Phase 1, monotherapyEXPERIMENTALPart A
Phase 1, combinationEXPERIMENTALPart B
Phase 2, monotherapyEXPERIMENTALPart A
Phase 2, combinationEXPERIMENTALPart B

Interventions

NameTypeDescription
AVZO-103DRUGSpecific dose in protocol specified schedule
Combination AgentDRUGPer label based on combination agent used
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites14

Key Inclusion Criteria: * Patient must be an adult, 18 years of age and older with an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1 and a life expectancy of \> 3 months. * Patients with histologically or cytologically confirmed locally advanced/metastatic malignancies for tumo...

Countries:United States
Unlock Eligibility Criteria